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Detection of serologic responses to GB virus Cl 
hepatitis G virus infection 
Shih-Yen Lo,(‘) Chia-Wen Ku,(l) Hsin-Chieh Ma,(l) Yi-Hwei Li,c2) Jui-Hung Yu,(~) Hsien-Hong Lin,c3) 
Ahai C. Lua,(‘) and Ming-Liang Leec4) 
Objectives: To investigate the prevalence of GB virus C/hepatitis G virus (GBV-C/HGV) and compare the serologic 
responses to various GBV-C/HGV markers in eastern Taiwan aborigines. 
Methods: We used RT-PCR and anti-HGenv u-plate to investigate the prevalence of GBV-C/HGV in eastern Taiwan 
aborigines. We also used ELISA, dot blot assay, and Western blot to detect the serologic responses to various GBV- 
C/HGV markers. 
Results: The prevalence of GBV-C/HGV RNA in the general population of eastern Taiwan aborigines is about 5% 
(17/317), while 14% (43/317) have anti-E2 antibodies. There were no significant differences in antibody titer against 
one consensus core peptide (PPSSAAACSRGSPR) between GBV-C/HGV RNA-positive and -negative sera. Only 
230f 42 serum samples positive in the anti-HGenv u-plate EIA assay were positive (55%) in the dot blot assay. No 
positive signal was detected by Western blot using either recombinant NS3 or commercial E2 proteins. 
Conclusions: Antibodies against one consensus core peptide (PPSSAAACSRGSPR) may not constitute a good 
marker for the detection of GBV-C/HGV viremia. For the detection of anti-E2 antibodies, the anti-HGenv u-plate 
assay is more sensitive than the dot blot assay. Western blot assay is not a sensitive method for detecting GBV- 
UHGV infection. 
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INTRODUCTION 
The genome of GB virus C/hepatitis G virus (GBV- 
UHGV) is a single-stranded, positive-sense RNA of 
approximately 9.4 kb that encodes a putative single 
large polyprotein in which the structural proteins are 
located in the N-terminal end and the non-structural 
proteins in the C-terminal end.‘” GBV-C/HGV RNA 
has been found in l-4% of healthy voluntary blood 
donors from different parts of the world.7 The trans- 
mission of GBV-C/HGV through parenteral and other 
routes has been reported.8-10 Infections with GBV- 
UHGV could lead to viral persistence.” 
It has been reported that GBV-C/HGV RNA is 
detected in some patients with fulminant non-A-E 
hepatitisi GBV-C/HGV has also been suggested to be 
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responsible for a significant number of acute and chronic 
cases of non-A-C hepatitis.i3 However, most GBV- 
C/HGV infections appear to be asymptomatic. 
There are two different methods commonly used 
to detect infection with GBV-C/HGV the reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
assay for viral RNA,i4 and the enzyme immunoassay 
(EIA) for anti-E2 antibodies. A significant negative cor- 
relation between the presence of viral RNA and the 
presence of anti-E2 antibody has been documented.9 
The presence of viral RNA in the serum of the patient 
represents viremia, while the presence of anti-E2 anti- 
bodies indicates the recovery from infection with GBV- 
CIHGV. 
The serologic responses of GBV-C/HGV-infected 
persons are not well studied. The prevalence of GBV- 
C/HGV in eastern Taiwan aborigines is unknown, though 
hepatitis A, B and C viruses are prevalent in the eastern 
Taiwan aborigines, who comprise the majority of Taiwan 
aborigines.i5,i6 In this study, we investigated the pre- 
valence of GBV-C/HGV and compared the serologic 
responses to various GBV-C/HGV markers in eastern 
Taiwan aborigines. 
MATERIALS AND METHODS 
Samples 
The serum samples for this investigation were obtained 
from a large-scale community-based cohort study of the 
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prevalence of hepatitis A, B and C viruses among 
aborigines in Hualien,Taiwan.lS Subjects were recruited 
from two Atayal villages, Fushiu and Sholin, from July 
1996 to June 1998. All persons aged 15 and older who 
resided in the selected communities were invited to 
participate. During the enrollment period for the cohort 
study, 2169 screening questionnaires were carried 
out. Of these cases, 1061 (48.9%) consented to have a 
physical examination and to have their blood sampled. 
Persons who agreed to have their blood tested tended 
to be older than those who refused to participate (mean 
age, 43 versus 34 years, P<O.OOl). There were more 
female subjects in the enrolled group than in the non- 
enrolled (54.0% versus 46.9%, P<O.OOl). All blood 
samples were collected in a portable refrigerator, 
delivered to the central laboratory for serum separation, 
and stored at -70°C until further analysis. 
The present investigation focused on a sample of 
317 subjects who were randomly selected from the 
larger study population (n=1061). Of the 317 study 
cases, 283 (89.3%) were Atayal. One hundred and 
eighty-six (58.7%) were women, and the average age 
was 45 years. 
RNA extraction and RT-PCR 
The nucleic acid was extracted from sera using the 
AcuPure DNA/RNA Extraction Kit (Biotronics Tech. 
Corp., Lowell, MA, USA). The procedure and con- 
ditions were the same as described in the manufacturer’s 
instructions. After nucleic acid extraction, the nucleic 
acid was used for cDNA synthesis by using random 
hexamer as the primer. 
The primers and conditions used in the nested PCR 
for the detection of GBV-C/HGV RNA were the same 
as those used to analyze the S’UTR of GBV-C/HGV.” 
Anti-HGenv u-plate 
The EIA kits (Microtiter plate assay; Boehringer 
Mannheim, Mannheim, Germany) were used in this 
study. The procedure and conditions were the same as 
described in the manufacturer’s instructions. 
Protein expression and Western blot 
The procedures used in protein expression and Western 
blot were as described previously.16,18 In this study, 
we used pGEX-2T (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) vector to express the gene frag- 
ment of GBV-C/HGV NS3 (from amino acid (aa) 1383 
to aa 1493) in Escherichia coli. The gene sequence of this 
fragment was determined by automatic sequencing. 
After expression, the E. co/i lysate containing 4 ug of 
either glutathione-S-transferase (GST) or GST-NS3 
fusion protein was used to perform Western blotting. For 
the analysis of GBV-C/HGV E2 protein, about 4 ug of 
the protein was also used in each reaction. The pET3a 
vector was used to express the truncated HCV E2 protein 
(from aa 384 to aa 660). Sera used in Western blotting 
were diluted lOOO-fold in TBS (10 mM Tris, pH 7, and 
150 mM NaCl) buffer containing 1% milk and 0.1% 
TX-100.16 
Dot blot (immunoblot) assay 
Various amounts (0.7 ug; 3.3 yg; 13.3 ug) of proteins 
(bovine serum albumin (BSA); GBV-C/HGV E2 protein 
from EIA u-plate kit) were blotted onto NC paper using 
HYBRI-DOT MANIFOLD (BRL Life Technology Inc., 
Carlsbad, CA, USA). Sera were diluted lOOO-fold. Other 
procedures are as described previously.19 Only reactions 
with increasing signals correlating well with the E2 pro- 
tein amount were defined as positive. 
ELISA 
For the detection of antibody against GBV-C/HGV 
core consensus peptide, we have modified the method 
described by Xiang et al.*O The core peptide 
(PPSSAAACSRGSPR) was conjugated with BSA; 2.4 
yg of this conjugated peptide was applied to 96-well 
enzyme-linked immunosorbent assay (ELISA) micro- 
titer plates in 0.025 M carbonate buffer (pH 9.6), and 
incubated for 4 h at 37°C. Following washing, GBV- 
C/HGV RNA-positive and GBV-C/HGV RNA-negative 
sera (diluted 1 : 20 in phosphate-buffered saline) were 
applied to the well, and the mixture was incubated 
overnight at 4°C. The wells were washed (3-5 times in 
phosphate-buffered saline plus 0.05% Tween-20) and 
alkaline phosphatase-conjugated goat anti-human 
immunoglobulin G was added (diluted 1 : 1000 in phos- 
phate-buffered saline), followed by incubation for 1 h 
at 37°C. The wells were washed again, and substrate 
was added (1 mg of p-nitrophenyl phosphate per mL in 
diethanolamine buffer). The reaction was stopped with 
3 M NaOH after 10-30 min, and the A405 was measured 
with an ELISA reader. Results were expressed as the 
ratio (S - NJ/N, i.e. ( absorbance of sample - background 
absorbance)/background absorbance). The background 
absorbance was determined by measuring the absorbance 
in wells that had received the same treatment as the 
others, except that no human serum was added. Three 
wells in each plate were used as the background. The 
average absorbance of these three wells is the back- 
ground absorbance of the microtiter plate. 
When the average signal was calculated, one sample 
detected as both GBV-CIHGV RNA and anti-HGenv 
u-plate positive was not included. 
RESULTS 
The prevalence of GBV-C/HGV RNA in the general 
population of eastern Taiwan aborigines is about 5% 
(17/317), while 14% (43/317) have anti-E2 antibodies. 
The coexistence of GBV-C/HGV RNA and HBsAg 
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was determined: two subjects were positive for both 
markers, 71 subjects were only HBsAg positive, 15 
subjects were only GBV-C/HGV RNA positive, and 229 
subjects were negative for both markers. The co- 
existence of GBV-C/HGV RNA and anti-HCV was also 
determined: five subjects were positive for both markers, 
91 subjects were only anti-HCV positive, 12 subjects 
were only GBV-C/HGV RNA positive, and 209 subjects 
were negative for both markers. Neither the association 
between GBV-C/HGV RNA and HBsAg (P=O.34) 
nor that between GBV-C/HGV RNA and anti-HCV 
(P=O.81) was significant. 
We have previously shown that the presence of 
GBV-C/HGV RNA does not correlate with elevated 
alanine aminotransferase (ALT) and/or aspartate amino- 
transferase (AST) activity. I6 Therefore, GBV-C/HGV 
infection may not cause the majority of clinically active 
hepatitis in most cases in this population. We have 
also measured the ALT and AST mean values of GBV- 
C/HGV RNA-positive and -negative serum samples 
(Table 1). Interestingly, both the ALT and AST mean 
values of GBV-C/HGV RNA-positive serum samples 
are higher than those of GBV-C/HGV RNA-negative 
ones. However, no significant differences in the levels 
of ALT (P=O.56) and AST (P=O.48) between GBV- 
C/HGV RNA-positive and -negative groups were 
detected. 
Similar to other reports, y~l” the detection of GBV- 
C/HGV RNA and the existence of anti-E2 antibodies 
were mutually exclusive, except in one subject. It will be 
easier to study the overall prevalence of GBV-C/HGV 
infection (viremia and sero-convalescence) if the sero- 
logic response to one specific viral protein is concordant 
with the presence of GBV-C/HGV RNA. Serologic 
responses to one consensus peptide (PPSSAAA- 
CSRGSPR) located in the putative core sequence have 
been demonstrated to be positive in GBV-C/HGV 
RNA-positive sera, but not in GBV-UHGV RNA- 
negative sera. 2o To determine whether the presence of 
antibodies against this core peptide is concordant with 
the presence of GBV-C/HGV RNA, we have performed 
the ELISA to determine serologic responses to the 
peptide. There were no significant differences in the 
signals between 16 GBV-C/HGV RNA-positive sera 
(average (S - N)/N=2.23? 1.56) and another 300 serum 
samples without GBV-UHGV RNA (average (,S - NJ/ 
N=2.13+-2.45). That is, the serologic response to this 
core peptide did not correlate well with the presence of 
GBV-C/HGV RNA. There were also no significant 
differences in the serologic responses to this core 
peptide between 16 HGV RNA-positive samples and 42 
Table 1. The ALT and AST Mean Values (W/L) of GBWJHGV 
RNA-positive and -negative serum samples in this study 
ALT 
AST 
Positive Negative 
41.6L60.1 32.9k32.9 
51.9t67.8 39.8236.1 
anti-HGenv u-plate-positive samples (average (S - N)/ 
N=2.01 k2.57); that is, antibody against this core peptide 
does not coexist with antibody against E2 protein. 
In addition to the commercially available anti- 
HGenv u-plate EIA assay, dot blot assay for various 
recombinant GBV-C/HGV proteins (El, E2, NS3, or 
NS4) has been used to study the serologic responses 
to GBV-UHGV infection.19,21 However, the correlation 
between the anti-HGenv u-plate ETA assay and the dot 
blot assay has not been studied. We have cloned and 
sequenced one fragment of the NS3 gene, which was 
fused to GST and expressed in E. coli (Figure lA), 
from one GBV-C/HGV-infected person. The fusion 
protein was gel-purified (Figure 1B) and used to perform 
dot blot assays. Not many positive signals were detected 
(data not shown). These data indicate that different re- 
combinant antigens and analytic methods have different 
sensitivities for detecting the serologic responses to the 
GBV-C/HGV infection.To compare the sensitivity of the 
anti-HGenv u-plate EIA with that of the dot blot assay, 
we have performed the dot blot assay using the same 
commercial E2 protein used in the anti-HGenv u-plate 
assay. Fourteen negative serum samples in the anti- 
HGenv u-plate assay were all negative in the dot blot 
assay. However, only 23 of 42 serum samples positive in 
the anti-HGenv u-plate assay were positive (55%) in the 
dot blot assay (Table 2). Therefore, for the detection of 
anti-E2 antibodies, the anti-HGenv u-plate assay is more 
sensitive than the dot blot assay. 
We have failed to detect the antibody response to 
GBV-C/HGV E2 or GST-gNS3 proteins (Figure 1B) by 
Western blotting, using nine sera strongly positive in 
the anti-HGenv u-plate assay (data not shown). For a 
comparison, we performed Western blot against GBV- 
C/HGV E2 and HCV (hepatitis C virus) E2 proteins 
using another six sera which showed positive antibody 
reactions for both HCV and GBV-C/HGV with com- 
mercially available kits. None of these six sera were 
positive against GBV-CIHGV E2 protein, while two 
were positive against recombinant HCV E2 protein 
(Figure 2). 
DISCUSSION 
Similar to the high prevalence of hepatitis A, B and C 
viruses,15 GBV-C/HGV infection in the general popu- 
Table 2. Comparison of the specificity and sensitivity between 
anti-HGenv u-plate and dot blot assays 
Anti-HGenv u-plate 
Positive Negative 
Dot blot 
Positive 23 0 
Negative 19 14 
Sensitivity=23/(23+19)=55%. Specificity=14/(14+0)=100%. 
Predictive positive value=23/(23+0)=100%. 
Predictive negative value=14/(14+19)=42%. 
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lation of eastern Taiwan aborigines is also high: about 
5% (17/317) of the people have GBV-C/I-IGV RNA, 
while 14% (43/317) have anti-E2 antibodies. 
There is no association between the presence of 
HBsAg and GBV-C/HGV RNA or between the pre- 
sence of anti-HCV and GBV-C/HGV RNA. Therefore, 
infection with HBV (or HCV) and the presence of 
GBV-C/HGV RNA appear to be independent of each 
other. 
The presence of GBV-C/HGV RNA is not 
associated with elevated ALT (and/or AST) valuesI 
suggesting that GBV-C/HGV infection may not cause 
the majority of clinically active hepatitis in most cases 
in this population. Interestingly, both the ALT and 
AST mean values of GBV-C/HGV RNA-positive serum 
samples are higher than those of GBV-C/HGV RNA- 
negative ones (Table l), although no significant differ- 
ences were found in these two groups. More GBV- 
97KD 
69KD 
45KD 
29KD 
18KD 
14KD 
Figure 1. Coomassie blue staining of the protein gels. (A) Protein expression in E. co/i: lane 1, GST; lane 2, GST-gNS3. 
(B) Proteins used for Western blotting: lane 1, BSA; lane 2, recombinant E2 protein from anti-HGenv u-plate kit; lane 3, 
gel-purified GST; lane 4, gel-purified recombinant GST-gNS3 protein. 
, 
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29KD 
Figure 2. Antibody detection by Western blotting. (A) Coomassie blue staining of the protein gel: lane 1, BSA; lane 2, GBV-UHGV E2 
protein from anti-HGenv u-plate kit; lane 3, E. co/i control lysate; lane 4, E. co/i lysate with recombinant HCV E2 protein. (B) Western 
blot result of the gel shown in (A). 
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C/HGV RNA-positive serum samples may be needed to 
further strengthen this observation. 
By using ELISA, we have shown that the serologic 
response to the core peptide did not correlate well 
with the presence of GBV-C/HGV RNA. Therefore, 
antibody against this consensus core peptide may not 
be a good marker for the detection of GBV-C/HGV 
viremia. Our data also indicate that antibody against this 
core peptide does not coexist with antibody against E2 
protein.These data may imply that not all GBV-C/HGV 
RNA encodes this core peptide. Our observations thus 
support a recent findingz2 that GBV-C/HGV, which does 
not contain this consensus core peptide, could replicate 
in the cells. 
For the detection of anti-E2 antibodies, our data 
suggest that the anti-HGenv u-plate assay is more 
sensitive than the dot blot assay (Table 2). Therefore, use 
of the dot blot assay rather than the anti-HGenv u-plate 
assay will probably lead to underestimation of the pre- 
valence of anti-E2 antibodies. 
We could detect HCV anti-E2 antibodies by using a 
Western blotting assay, but not HGV anti-E2 antibodies 
(Figure 2). Therefore, Western blot is not a good tool to 
detect HGV infection. 
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